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Eor How Long Should Treatment
ith Clopidogrel Be Continued
fter Coronary Stent Implantation?
n their editorial (1) in JACC on the analysis of the results of the
ARGET study (2), Tcheng and Campbell try to provide answers
o five key questions regarding clopidogrel therapy as an adjunct to
ercutaneous coronary intervention (PCI). The fifth question is:
ow long should treatment be continued? The recommendation
n the editorial is to continue therapy for one year. This is based on
esults of the PCI-CURE and CREDO studies (3,4). However,
oth these studies compared a strategy that included both pretreat-
ent (before PCI) and long-term treatment after PCI to a strategy
f treatment for one month only after PCI. In both these trials, the
rst strategy was superior; however, it is not clear whether the
ong-term benefit (from one month to one year) is related to the
retreatment or to the continuation of clopidogrel beyond one
onth after PCI.
Data presented in the analysis of TARGET (2) show that
retreatment is associated with additional benefit, beyond one
onth. Death or myocardial infarction (MI) rates at one month
ere 6.2% and 10.1%, with and without pretreatment, respectively
3.9% absolute difference). This absolute difference increased to
.2% at six months (7.8% compared to 13% with and without
retreatment). Thus, the pretreatment itself explains additional
bsolute reduction of 1.3% in death or MI (from one to six
onths). The conclusion from this analysis is that most of the
enefit in PCI-CURE and CREDO is from the pretreatment
ather than from the continuation of clopidogrel treatment to one
ear. I believe that Tcheng and Campbell should alter their fifth
ecommendation because, based on the above analysis, it is unclear
hether continuation of clopidogrel treatment beyond one month
fter PCI is associated with any benefit. I would certainly agree
hat pretreatment is highly recommended.
oseph Rozenman, MD, FACC
he E. Wolfson Medical Center
ardiology
.O. Box 5
olon 58100
srael
-mail: rozenman@wolfson.health.gov.il
doi:10.1016/j.jacc.2004.01.007
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y his letter, Dr. Rozenman raises not only one but several critical
ssues regarding the optimal duration of clopidogrel treatment.
hese include the interpretation of clinical trial results relative to
rimary versus substudy analyses, and (implicitly) the impact of
conomics on applying trial findings to the real world.
The interpretation of clinical trial results is best approached with
igor and caution. The PCI-CURE analysis (1), though prospectively
efined, is nevertheless a post-randomization substudy better consid-
red as “hypothesis-generating.” Confounders may have been intro-
uced that could account for some of the differences observed at both
0 days and long-term. It is not possible to determine the relative
ontributions of pre-treatment versus treatment after one month to
he long-term efficacy results observed in PCI-CURE. What is clear
s that additional benefits accrue to patients in the active treatment
rm between 30 days and one year.
The approach to answering the duration-of-therapy question
ltimately will require a series of randomized, prospective trials. A
omponent of this question is approached in CREDO (2) (direct
omparison of pre-PCI loading followed by long-term therapy,
ersus “uncovered” PCI, followed by post-PCI treatment without
oading, followed by four weeks of short-term therapy). Conducted
n a prospective, randomized fashion, the result was actually
egative at the primary 28-day end point (relative risk reduction
RRR] of 18.5%, 95% confidence interval [CI] 14.2% to 41.8%,
 0.23). What was observed in the CREDO trial was a greater
bsolute difference in the composite end point rates between 29
ays and one year (after patients in the comparator arm had been
laced on placebo treatment) than that seen between PCI and 28
ays. In CREDO, it was not until after the first 28 days that the
vent curves separated sufficiently to have a statistically significant
ifference (29-day to one-year RRR of 37.4%, 95% CI 1.8% to
0.1%, p  0.04, resulting in an overall one-year RRR of 26.9%,
5% CI 3.9% to 44.4%, p  0.02). Given the similar trend
bserved in PCI-CURE (and the absence of the definitive trials to
ddress the issue), it would appear that short-term therapy is best
hought of as reducing the propensity for early subacute stent
hrombosis, whereas longer-term therapy is efficacious in reducing
dverse cardiovascular events including death, myocardial infarc-
ion, and stroke.
Economics become central to rational treatment when a ther-
peutic imparts a high direct cost to the consumer and when the
ost-effectiveness is marginal. Duration of therapy would not be an
ssue if clopidogrel were inexpensive. Economic issues, however,
o not invalidate efficacy considerations. Instead, we should focus
n the “cost of living” component by identifying strategies, both
ocally and nationally, for assuring the delivery of optimal treat-
ents to those who stand to benefit.
ames E. Tcheng, MD, FACC
ssociate Professor of Medicine
uke University Medical Center
021 Duke North Pavilion
400 Pratt Street
urham, NC 27705
-mail: tchen001@mc.duke.edudoi:10.1016/j.jacc.2004.01.008
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herapeutic Failure or Resistance to Aspirin
um et al. (1) recently published a highly cited study about the
otential clinical consequences of aspirin resistance as assessed by
ggregometry in patients undergoing elective cardiac catheterization.
In a recent reply to comments raised by Steinhubl et al. (2),
opol and colleagues (3) acknowledge the real possibility of a type
I error to detect an association between long-term outcomes and
spirin-resistance status as determined by the Platelet Function
nalyzer (PFA-100). In fact, this is a little surprising, because
revious studies indicated that PFA-100 results are highly predic-
ive of clinical outcome in stroke patients receiving aspirin (4) and
n patients with percutaneous interventions of peripheral arteries
ho received clopidogrel (5). It is interesting to note that, based on
he percentages of aspirin-sensitive and aspirin-resistant-patients
resented in Gum et al. (1), Gum et al. (6), and Topol et al. (3),
he total number of patients experiencing adverse events is 35 and
3 for aggregometry and PFA-100, respectively. This inconsis-
ency needs further clarification.
What should make the reader more concerned is the high
ikelihood for an alpha error regarding the main outcome of Gum
t al. (1) concerning aggregometry: the total number of aspirin-
esistant subjects is limited (n  17 of 326), of whom only four
24%) experienced an adverse outcome, as compared to 10% of
spirin-responsive patients. Therefore, statistical significance (p 
.03) relies on only four events in aspirin-resistant patients, and
ven one event less in this group would be likely to yield an
nsignificant p value. Considering that the investigators used two
ethods to assess aspirin resistance (6), the PFA-100 and the
ggregometry, a p value correction, if done for the two end points,
ould also result in an insignificant p value. Thus, statistical
ignificance is not very robust.
The late occurrence of events is conspicuous because it contrasts
ith what has been observed for the clinical efficacy of aspirin
ersus placebo, where mortality curves cross after 18 to 24 months
7). This further increases the chances for an alpha error.
Finally, Topol et al. (3) discuss the poor correlation between
ggregometry and PFA-100. This is not surprising when differ-
nces between methods are considered. The PFA-100 fulfills
everal of the characteristics of an ideal and rather physiological
latelet-function test (8,9). First, whole blood is used rather than
latelet-rich plasma. Second, it is a high shear system. This is
mportant, because the cyclo-oxygenase inhibitor aspirin and the
urinergic receptor inhibitor clopidogrel are primarily used for
rterial indications, which are characterized by high shear rates.
In summary, several trials (1,4,5,10) have generated interest in
nvestigating the clinical consequences of aspirin and clopidogrel
on-responsiveness, which, it is hoped, will result in adequately
owered confirmatory studies with pivotal results.ernd Jilma, MD
epartment of Clinical Pharmacology
ienna University Hospital
-1090 Wien, Austria
-mail: Bernd.Jilma@univie.ac.at
doi:10.1016/j.jacc.2004.01.011
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n response to the letter by Dr. Jilma, I believe we have fully
ddressed his concerns in our primary report (1) and the subse-
uent correspondence (2). The conclusion of our study was that
further investigation to confirm our findings . . . should be per-
ormed.” We fully acknowledged the relatively small sample size,
umber of events, and potential for alpha error (1). We also duly
oted the poor correlation of the Platelet Function Analyzer
PFA) results despite Dr. Jilma’s expectations.
Rather than investigator “resistance,” we invite Dr. Jilma to
erform meaningful prospective research to define further the
atural history of anti-platelet drug lack of responsiveness.
ric J. Topol, MD
he Cleveland Clinic Foundation
epartment of Cardiovascular Medicine
500 Euclid Ave. F-25
leveland, OH 44195
-mail: Topole@ccf.org
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